Effect Of Personalized Approach To Therapy In Non-Small Cell Lung Cancer (Nsclc) With Liver Metastasis With Immunotherapy On Outcomes.

e21504 Background: Patients with NSCLC with liver metastasis tend to have significantly reduced overall survival (OS) compared to NSCLC with metastasis to other sites. We aimed looking at the patients with lung cancer at our institution over a five year period and assess the outcome of NSCLC with liver metastasis based on different treatment modalities. Methods: This is a retrospective study of patients with NSCLC and liver metastasis over the past five years. Patient data was securely collected and stratified based on demographics, histology, driver mutation analysis, date of diagnosis, place of metastasis, date of treatment, types of treatment received, and date of death, as applicable. Results: Eight of 132 patients had liver metastasis. Out of which one had SCLC and was treated with carboplatin-etoposide-atezolizumab with OS of 17 months. Remaining seven were NSCLC where five patients had adenocarcinoma and 2 had squamous histology. Pembrolizumab was part of treatment for all 4 patients with adenocarcinoma. 5th patient was treated with chemotherapy and had OS of 2 months. Female to male ratio 3:2 for adenocarcinoma and 0:2 for squamous histology with equal ethnic distribution. Two patients had squamous histology, both males and had average OS of 4.5 months. Conclusions: Patients with liver metastasis regardless of the histology, have short overall survival. However it was observed that such patients when treated with immunotherapy as part of their treatment modality do much better compared to those who did not. Specifically immunotherapy benefits are more pronounced in patients with adenocarcinoma histology compared to squamous. However further studies are indicated to evaluate personalized approach to therapy in NSCLC with liver metastasis. Our study was limited based on our limited number of patients.